antibody

Goat anti-KIP1/CDKN1B (internal) Antibody

MBS421279

0.1 mg

300 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog, cow

western blot, immunohistochemistry, enzyme immunoassay

Antibody

Goat anti-KIP1/CDKN1B (internal) Antibody

KIP1/CDKN1B

Goat Anti-P27KIP1 / CDKN1B (C Terminus) Antibody; CDKN1B; KIP1; cyclin-dependent kinase inhibitor 1B (p27, Kip1); CDKN4; P27KIP1; cyclin-dependent kinase inhibitor 1B; CDKN1B antibody; KIP1 antibody; cyclin-dependent kinase inhibitor 1B (p27; Kip1) antibody; CDKN4 antibody; P27KIP1 antibody; cyclin-dependent kinase inhibitor 1B antibody; KIP1 / CDKN1B (internal)

cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; p27Kip1

CDKN1B

KIP1

CDKN1B; CDKN1B; KIP1; MEN4; CDKN4; MEN1B; P27KIP1; KIP1

CDN1B_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human, Mouse, Rat, Cat, Dog, Pig, Cow

198

KRPATDDSSTQNK

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

Peptide ELISA: Antibody detection limit dilution 1: 32000. Immunohistochemistry: In paraffin embedded Human Prostate shows nuclear staining of secretory cells. Recommended concentration, 5-10ug/ml. Western Blot: Approx 26kDa band observed in lysates of Human Prostate and of Hepatoblastoma cell line HepG2 (calculated MW of 22.1kDa according to NP_004055.1). The observed molecular weight corresponds to earlier findings in literature with different antibodies (Xia et al, Proc Natl Acad Sci U S A.2005 Sep 27;102(39): 14028-33; PMID: 16169901). Recommended concentration: 0.1-0.3ug/ml.

Immunogen: Peptide with sequence C-KRPATDDSSTQNK, from the internal region of the protein sequence according to NP_004055.1. Epitope: Internal region

4757962

NP_004055.1

NM_004064.4

22,073 Da

AGE-RAGE Signaling Pathway In Diabetic Complications (1319988); AGE-RAGE Signaling Pathway In Diabetic Complications (1319775); AKT Phosphorylates Targets In The Cytosol Pathway (1269189); Adaptive Immune System Pathway (1269171); AhR Pathway (755436); C-MYB Transcription Factor Network Pathway (138073); Cell Cycle Pathway (1269741); Cell Cycle Checkpoints Pathway (1269742); Cell Cycle, Mitotic Pathway (1269763); Cell Cycle Pathway (198811)

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]

p27Kip1: a cell-cycle regulatory protein that Interacts with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1. May mediate TGF beta-induced g1 arrest. Its degradation is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Protein type: Oncoprotein; Inhibitor; Cell cycle regulation; Protein kinase, regulatory subunit. Chromosomal Location of Human Ortholog: 12p13.1-p12. Cellular Component: cytoplasm; cytosol; endosome; nucleoplasm; nucleus. Molecular Function: caspase activator activity; chaperone binding; cyclin-dependent protein kinase inhibitor activity; Hsp70 protein binding; protein binding; protein complex binding; protein phosphatase binding; transforming growth factor beta receptor, cytoplasmic mediator activity. Biological Process: autophagic cell death; caspase activation; cell cycle arrest; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; G1/S transition of mitotic cell cycle; inner ear development; negative regulation of apoptosis; negative regulation of cell growth; negative regulation of cell motility; negative regulation of cell proliferation; negative regulation of cyclin-dependent protein kinase activity; negative regulation of kinase activity; negative regulation of mitotic cell cycle; negative regulation of phosphorylation; negative regulation of transcription, DNA-dependent; Notch signaling pathway; positive regulation of cell cycle; positive regulation of cell proliferation; positive regulation of cyclin-dependent protein kinase activity; positive regulation of microtubule polymerization; positive regulation of protein catabolic process; potassium ion transport; regulation of cyclin-dependent protein kinase activity; response to amino acid stimulus; response to cadmium ion; response to drug; response to estradiol stimulus; response to glucose stimulus; response to hypoxia; response to peptide hormone stimulus; sensory perception of sound. Disease: Multiple Endocrine Neoplasia, Type Iv

0.1 mg

300 USD